Highly specific auto-antibodies against claudin-18 isoform 2 induced by a chimeric HBcAg virus-like particle vaccine kill tumor cells and inhibit the growth of lung metastases

Cancer Research

Volumn 71, Issue 2, 2011, Pages 516-527

  Klamp, Thorsten ^a   Schumacher, Jens ^a   Huber, Georg ^a,d   Kühne, Christoph ^a   Meissner, Ulrich ^a   Selmi, Abderraouf ^a   Hiller, Thomas ^a   Kreiter, Sebastian ^b   Markl, Jürgen ^a   Türeci, Özlem ^c   Sahin, Ugur ^a,b  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b Center of Translational Oncology and Immunology   (Germany)

^c Ganymed Pharmaceuticals AG   (Germany)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; CHIMERIC ANTIBODY; CLAUDIN 18; DIFFERENTIATION ANTIGEN; EPITOPE; HEPATITIS B CORE ANTIGEN; HEPATITIS B VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL LINEAGE; CELL MEDIATED CYTOTOXICITY; CONTROLLED STUDY; EPITOPE MAPPING; HUMAN; HUMAN CELL; IMMUNIZATION; IN VITRO STUDY; LUNG METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA SPLICING; TUMOR CELL; VIRUS LIKE AGENT;

ADENOCARCINOMA; AMINO ACID SEQUENCE; ANIMALS; ANTIBODY SPECIFICITY; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; AUTOANTIBODIES; CANCER VACCINES; CELL LINE, TUMOR; CHO CELLS; CRICETINAE; CRICETULUS; HEK293 CELLS; HEPATITIS B CORE ANTIGENS; HEPATITIS B VIRUS; HUMANS; LUNG NEOPLASMS; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; PROTEIN ISOFORMS; RABBITS; STOMACH NEOPLASMS; VACCINES, VIRUS-LIKE PARTICLE;

EID: 78751471791     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-2292     Document Type: Article

References (50)

1. Oldham RK, Dillman RO. Monoclonal antibodies in cancer therapy: 25 years of progress. J Clin Oncol 2008;26:1774-7.
2. Griggs J, Zinkewich-Peotti K. The state of the art: immune-mediated mechanisms of monoclonal antibodies in cancer therapy. Br J Cancer 2009;101:1807-12.
3. Nimmerjahn F, Ravetch JV. Antibodies, Fc receptors and cancer. Curr Opin Immunol 2007;19:239-45.
4. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002;99:754-8.
5. Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, MissaleG, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER- 2/neu-positive metastatic breast cancer. J Clin Oncol 2008;26: 1789-96.
6. Bibeau F, Lopez-Crapez E, Di FF, Thezenas S, Ychou M, Blanchard F, et al. Impact of Fc(gamma)RIIa-Fc(gamma)RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 2009;27:1122-9.
7. Racila E, Link BK, Weng WK, Witzig TE, Ansell S, Maurer MJ, et al. A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma. Clin Cancer Res 2008;14:6697-703.
8. Dalle S, Thieblemont C, Thomas L, Dumontet C. Monoclonal antibodies in clinical oncology. Anticancer Agents Med Chem 2008; 8:523-32.
9. Scolnik PA. mAbs: a business perspective. MAbs 2009;1:179-84.
10. Xiang SD, Scalzo-Inguanti K, Minigo G, Park A, Hardy CL, Plebanski M. Promising particle-based vaccines in cancer therapy. Expert Rev Vaccines 2008;7:1103-19.
11. Spohn G, Bachmann MF. Exploiting viral properties for the rational design of modern vaccines. Expert Rev Vaccines 2008;7:43-54.
12. Chackerian B. Virus-like particles: flexible platforms for vaccine development. Expert Rev Vaccines 2007;6:381-90.
13. Milich DR, Chen M, Schodel F, Peterson DL, Jones JE, Hughes JL. Role of B cells in antigen presentation of the hepatitis B core. Proc Natl Acad Sci U S A 1997;94:14648-53.
14. Pumpens P, Grens E. HBV core particles as a carrier for B cell/T cell epitopes. Intervirology 2001;44:98-114.
15. Schodel F, Moriarty AM, Peterson DL, Zheng JA, Hughes JL, Will H, et al. The position of heterologous epitopes inserted in hepatitis B virus core particles determines their immunogenicity. J Virol 1992;66:106-14.
16. Karanjawala ZE, Illei PB, Ashfaq R, Infante JR, Murphy K, Pandey A, et al. New markers of pancreatic cancer identified through differential gene expression analyses: claudin 18 and annexin A8. Am J Surg Pathol 2008;32:188-96.
17. Sahin U, Koslowski M, Dhaene K, Usener D, Brandenburg G, Seitz G, et al. Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. Clin Cancer Res 2008;14:7624-34.
18. Salfeld J, Pfaff E, Noah M, Schaller H. Antigenic determinants and functional domains in core antigen and e antigen from hepatitis B virus. J Virol 1989;63:798-808.
19. 2+-chelate affinity chromatography. J Virol Methods 1999;77:189-97.
20. Vogel M, Vorreiter J, Nassal M. Quaternary structure is critical for protein display on capsid-like particles (CLPs): efficient generation of hepatitis B virus CLPs presenting monomeric but not dimeric and tetrameric fluorescent proteins. Proteins 2005;58:478-88.
21. Serwer P, Khan SA, Griess GA. Non-denaturing gel electrophoresis of biological nanoparticles: viruses. J Chromatogr A 1995; 698:251-61.
22. Harris JR. Negative staining of thinly spread biological samples. Methods Mol Biol 2007;369:107-42.
23. Meissner U, Gatsogiannis C, Moeller A, Depoix F, Harris JR, Markl J. Comparative 11Å structure of two molluscan hemocyanins from 3D cryo-electron microscopy. Micron 2007;38:754-65.
24. Wynne SA, Crowther RA, Leslie AG. The crystal structure of the human hepatitis B virus capsid. Mol Cell 1999;3:771-80.
25. Niimi T, Nagashima K, Ward JM, Minoo P, Zimonjic DB, Popescu NC, et al. Claudin-18, a novel downstream target gene for the T/EBP/ NKX2.1 homeodomain transcription factor, encodes lung- and stomach- specific isoforms through alternative splicing. Mol Cell Biol 2001;21:7380-90.
26. Cragg MS, Walshe CA, Ivanov AO, Glennie MJ. The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun 2005;8:140-74.
27. Ruuls SR, Lammerts van Bueren JJ, van de Winkel JG, Parren PW. Novel human antibody therapeutics: the age of the UmAbs. Biotechnol J 2008;3:1157-71.
28. Karpenko LI, Ivanisenko VA, Pika IA, Chikaev NA, Eroshkin AM, Veremeiko TA, et al. Insertion of foreign epitopes in HBcAg: how to make the chimeric particle assemble. Amino Acids 2000;18:329-37.
29. Ortaldo JR, Woodhouse C, Morgan AC, Herberman RB, Cheresh DA, Reisfeld R. Analysis of effector cells in human antibody-dependent cellular cytotoxicity with murine monoclonal antibodies. J Immunol 1987;138:3566-72.
30. Kratz PA, Bottcher B, Nassal M. Native display of complete foreign protein domains on the surface of hepatitis B virus capsids. Proc Natl Acad Sci USA 1999;96:1915-20.
31. Beers SA, Chan CH, French RR, Cragg MS, Glennie MJ. CD20 as a target for therapeutic type I and II monoclonal antibodies. Semin Hematol 2010;47:107-14.
32. Zinkernagel RM, Pircher HP, Ohashi P, Oehen S, Odermatt B, Mak T, et al. T and B cell tolerance and responses to viral antigens in transgenic mice: implications for the pathogenesis of autoimmune versus immunopathological disease. Immunol Rev 1991;122:133-71.
33. Wardemann H, Yurasov S, Schaefer A, Young JW, Meffre E, Nussenzweig MC. Predominant autoantibody production by early human B cell precursors. Science 2003;301:1374-7.
34. Dyer MR, Renner WA, Bachmann MF. A second vaccine revolution for the new epidemics of the 21st century. Drug Discov Today 2006;11:1028-33.
35. Goodnow CC. B-cell tolerance. Curr Opin Immunol 1992;4:703-10.
36. Ferry H, Jones M, Vaux DJ, Roberts IS, Cornall RJ. The cellular location of self-antigen determines the positive and negative selection of autoreactive B cells. J Exp Med 2003;198:1415-25.
37. Bachmann MF, Rohrer UH, Kundig TM, Burki K, Hengartner H, Zinkernagel RM. The influence of antigen organization on B cell responsiveness. Science 1993;262:1448-51.
38. Ferry H, Leung JC, Lewis G, Nijnik A, Silver K, Lambe T, et al. B-cell tolerance. Transplantation 2006;81:308-15.
39. Jennings GT, Bachmann MF. The coming of age of virus-like particle vaccines. Biol Chem 2008;389:521-36.
40. Spohn G, Bachmann MF. Therapeutic vaccination to block receptorligand interactions. Expert Opin Biol Ther 2003;3:469-76.
41. Hunter Z, Smyth HD, Durfee P, Chackerian B. Induction of mucosal and systemic antibody responses against the HIV coreceptor CCR5 upon intramuscular immunization and aerosol delivery of a virus-like particle based vaccine. Vaccine 2009;28:403-14.
42. Ramqvist T, Andreasson K, Dalianis T. Vaccination, immune and gene therapy based on virus-like particles against viral infections and cancer. Expert Opin Biol Ther 2007;7:997-1007.
43. Tegerstedt K, Lindencrona JA, Curcio C, Andreasson K, Tullus C, Forni G, et al. A single vaccination with polyomavirus VP1/VP2Her2 virus-like particles prevents outgrowth of HER-2/neu-expressing tumors. Cancer Res 2005;65:5953-7.
44. Gathuru JK, Koide F, Ragupathi G, Adams JL, Kerns RT, Coleman TP, et al. Identification of DHBcAg as a potent carrier protein comparable to KLH for augmenting MUC1 antigenicity. Vaccine 2005;23:4727-33.
45. Kazaks A, Balmaks R, Voronkova T, Ose V, Pumpens P. Melanoma vaccine candidates from chimeric hepatitis B core virus-like particles carrying a tumor-associated MAGE-3 epitope. Biotechnol J 2008;3:1429-36.
46. Zhang Y, Song S, Liu C, Wang Y, Xian X, He Y, et al. Generation of chimeric HBc proteins with epitopes in E. coli: formation of virus-like particles and a potent inducer of antigen-specific cytotoxic immune response and anti-tumor effect in vivo. Cell Immunol 2007;247: 18-27.
47. Storni T, Ruedl C, Schwarz K, Schwendener RA, Renner WA, Bachmann MF. Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects. J Immunol 2004;172:1777-85.
48. Kong J, Diao Z, Deng X, Zhong H, Yao W, Hu X. Anti-tumor effects of immunotherapeutic peptide on the treatment of hepatocellular carcinoma with HBc carrier. Oncol Rep 2007;18:279-85.
49. Dorn DC, Lawatscheck R, Zvirbliene A, Aleksaite E, Pecher G, Sasnauskas K, et al. Cellular and humoral immunogenicity of hamster polyomavirus-derived virus-like particles harboring a mucin 1 cytotoxic T-cell epitope. Viral Immunol 2008;21:12-27.
50. Li M, Bharadwaj U, Zhang R, Zhang S, Mu H, Fisher WE, et al. Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer. Mol Cancer Ther 2008;7:286-96.